Brokerages Set Liquidia Corporation (NASDAQ:LQDA) PT at $39.67

Liquidia Corporation (NASDAQ:LQDA) has been given an average rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $39.6667.

A number of research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Needham & Company LLC boosted their target price on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen downgraded shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. HC Wainwright lifted their price objective on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 price objective on shares of Liquidia in a report on Tuesday, November 4th.

Insiders Place Their Bets

In other news, CEO Roger Jeffs sold 66,610 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $2,493,212.30. Following the completion of the sale, the chief executive officer directly owned 1,037,528 shares in the company, valued at approximately $38,834,673.04. This represents a 6.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jason Adair sold 688 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $41.65, for a total value of $28,655.20. Following the sale, the insider directly owned 211,169 shares in the company, valued at approximately $8,795,188.85. This trade represents a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 216,820 shares of company stock valued at $8,102,685 in the last quarter. Company insiders own 26.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia during the fourth quarter worth about $25,000. Covestor Ltd lifted its holdings in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Liquidia during the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Liquidia during the 3rd quarter worth approximately $34,000. Finally, NewEdge Advisors LLC bought a new position in Liquidia in the second quarter valued at approximately $25,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Trading Down 4.2%

Shares of NASDAQ:LQDA opened at $33.59 on Friday. Liquidia has a 12-month low of $11.26 and a 12-month high of $46.67. The business has a 50 day moving average of $37.56 and a 200-day moving average of $30.30. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The stock has a market cap of $2.92 billion, a PE ratio of -23.33, a P/E/G ratio of 0.94 and a beta of 0.46.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).